Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Registry of Outcomes of Dezawa MuseCells®

NCT07645989 · tracked via the Priya Life Science Mexico tracker
Sponsor
MuseCell Innovations Pte LTD
Phase
Observational
Started
2026-07-01
Last updated
2026-06-12

Condition(s) studied

Osteoarthritis (OA)LongevityWound CarePainOrthopaedic

Investigational drug(s) / intervention(s)

MuseCell Treatment

MuseCell Treatment: Patients undergoing treatment with Dezawa MuseCells

Study summary

The goal of this observational study is to learn about the long-term effects of Dezawa MuseCells to treat various diseases.

The Primary Goal: What is the short-term and long- term outcomes of Dezawa Musecells? Participants treated with Dezawa MuseCells as part of their regular medical care and will answer online survey questions about symptoms and clinical outcomes for 5 years.

Eligibility

Sex
ALL
Min age
—
Max age
89 Years
Healthy volunteers
No
Inclusion Criteria: 1. Received Dezawa MuseCells® as Part of Routine Clinical Care 2. Patients ( and/or authorized representative) capable of providing informed consent and participating in long-term follow-up. 3. Willingness to Complete Online Survey Assessments 4. Participants must have reliable access to email or a mobile device and be willing to complete digital surveys at scheduled intervals over a 5-year period. 5. Diagnosis of a Condition for Which Dezawa MuseCells® Were Administered Includes, but is not limited to, neurologic, musculoskeletal, cardiovascular, immunologic, and systemic degenerative conditions. 6. Ability to Communicate in the Registry's Supported Language 7. Participants must be able to read and respond to registry surveys in the designated study language. 8. Enrollment Within 12 Months of MuseCell® Administration Exclusion Criteria: 1. Not Receive Dezawa MuseCells®-Individuals who have not been treated with Dezawa MuseCells® or received a counterfeit/non-licensed product cannot be included. 2. Unable or Unwilling to Provide Informed Consent Includes individuals with cognitive impairment who lack a legally authorized representative willing to consent on their behalf. 3. Inability to Participate in Long-Term Digital Follow-Up 4. Concurrent Participation in an Interventional Clinical Trial Affecting Outcomes 5. History of Malignancy Diagnosed Within the Past 12 Months 6. Excludes patients with active or recently treated cancer unless their treating physician determines participation poses no additional safety concerns. 7. Any Condition That, in the Investigator's Judgment, Would Compromise Data Quality 8. Use of Non-Licensed or Counterfeit "Muse-like" Cells Ensures that registry data reflect outcomes of authentic Dezawa MuseCells® produced under licensed methods. 9. Pregnant or Actively Breastfeeding at Time of Enrollment

Primary outcome measure(s)

  • Change in Patient Reported Symptom Severity — Baseline; 1 month; 3 months; 6 months; 12 months; annually through 5 years.
    Change in condition-specific symptom severity following Dezawa MuseCell® administration.

Trial sites (2)

FacilityCityRegionStatus
Bioreset Medical North Palm Beach Florida Recruiting
Regene Labs Guadalajara Mexico Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07645989 on ClinicalTrials.gov ↗ ← All trials in Mexico